Oxtriphylline | CAS#4499-40-5 | bronchodilator

MedKoo Cat#: 318402 | Name: Oxtriphylline

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Oxtriphylline is a cough medicine derived from xanthine that acts as a bronchodilator to open up airways in the lung. Chemically, it is a salt of choline and theophylline. Oxtriphylline classifies as an expectorant.

Chemical Structure

Oxtriphylline

CAS#4499-40-5

Theoretical Analysis

MedKoo Cat#: 318402

Name: Oxtriphylline

CAS#: 4499-40-5

Chemical Formula: C12H21N5O3

Exact Mass: 283.1644

Molecular Weight: 283.33

Elemental Analysis: C, 50.87; H, 7.47; N, 24.72; O, 16.94

Price and Availability

Size	Price	Availability	Quantity
500mg	USD 700.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Oxtriphylline, Cholinetheophyllinate, Brondaxin, Brondecon, Choledyl

IUPAC/Chemical Name

1,3-dimethyl-2-oxopurin-6-olate;2-hydroxyethyl(trimethyl)azanium

InChi Key

SOELXOBIIIBLRJ-UHFFFAOYSA-M

InChi Code

InChI=1S/C7H8N4O2.C5H14NO/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;1-6(2,3)4-5-7/h3,12H,1-2H3;7H,4-5H2,1-3H3/q;+1/p-1

SMILES Code

[O-]C1=C2N=CN=C2N(C)C(N1C)=O.C[N+](C)(CCO)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Choline theophyllinate (Oxtriphylline) is a choline salt of theophylline with anti-asthmatic activity.

In vitro activity:

TBD

In vivo activity:

TBD

	Solvent	mg/mL	mM
Solubility
	Water	250.0	882.37

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 283.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

TBD

In vitro protocol:

TBD

In vivo protocol:

TBD

1: Adikusuma W, Chou WH, Lin MR, Ting J, Irham LM, Perwitasari DA, Chang WP, Chang WC. Identification of Druggable Genes for Asthma by Integrated Genomic Network Analysis. Biomedicines. 2022 Jan 6;10(1):113. doi: 10.3390/biomedicines10010113. PMID: 35052792; PMCID: PMC8773254. 2: Hendeles L, Jenkins J, Temple R. Revised FDA labeling guideline for theophylline oral dosage forms. Pharmacotherapy. 1995 Jul-Aug;15(4):409-27. PMID: 7479193. 3: Luterotti S, Maysinger D. Chemiluminometric determination of choline-related substances in pharmaceutical preparations by dot-blot. J Pharm Biomed Anal. 1994 Sep;12(9):1083-90. doi: 10.1016/0731-7085(94)00050-6. PMID: 7803556. 4: Pillai G, Miller R, Rambiritch V. The theophylline content of bronchodilator preparations on the South African market. S Afr Med J. 1991 Sep 7;80(5):240-3. PMID: 1887352. 5: Mondal BK, Beck PR, Gregory J, le Cotonnec JY, Clarke I. Pharmacokinetic study of controlled-release choline theophyllinate in elderly patients. Br J Clin Pract. 1990 Jun;44(6):223-5. PMID: 2206815. 6: Cartwright RG, Cartlidge PH, Rutter N, Melia CD, Davis SS. Transdermal delivery of theophylline to premature infants using a hydrogel disc system. Br J Clin Pharmacol. 1990 May;29(5):533-9. doi: 10.1111/j.1365-2125.1990.tb03676.x. PMID: 2350529; PMCID: PMC1380152. 7: Samaan S, Fox R. The effect of smoking on theophylline kinetics in healthy and asthmatic elderly males. J Clin Pharmacol. 1989 May;29(5):448-50. doi: 10.1002/j.1552-4604.1989.tb03360.x. PMID: 2738176. 8: Tatsis G, Danos J, Gaga M, Pantelakis D, Veslemes M, Jordanoglou J. A single- blind crossover study of two different slow release theophylline preparations. J Int Med Res. 1988 Nov-Dec;16(6):452-8. doi: 10.1177/030006058801600607. PMID: 3069520. 9: Subramaniam S, Dhand R, Garg SK, Sharma PL. A steady state comparison of three theophylline formulations in adult stable asthmatics. Indian J Med Res. 1988 May;87:509-15. PMID: 3169909. 10: Pang JA, Zhang YG, Swaminathan R. The pharmacokinetics and efficacy of slow- release theophylline with asymmetric dosing in asthmatic Chinese. Chest. 1988 Apr;93(4):785-9. doi: 10.1378/chest.93.4.785. PMID: 3349835. 11: Hibberd SG, Alveyn C, Coombes EJ, Holgate ST. Acute and chronic pharmacokinetics of asymmetrical doses of slow release choline theophyllinate in asthma. Br J Clin Pharmacol. 1986 Sep;22(3):337-41. doi: 10.1111/j.1365-2125.1986.tb02896.x. PMID: 3768245; PMCID: PMC1401120. 12: Rivera-Calimlim L, Calimlim JF, Liang R, Lasagna L, Diamond GL. Bioavailability and pharmacological effects of two slow-release theophylline preparations: intrasubject tablet-to-tablet variability. J Asthma. 1986;23(3):113-22. doi: 10.3109/02770908609077485. PMID: 3528119. 13: Rhind GB, Connaughton JJ, McFie J, Douglas NJ, Flenley DC. Sustained release choline theophyllinate in nocturnal asthma. Br Med J (Clin Res Ed). 1985 Dec 7;291(6509):1605-7. doi: 10.1136/bmj.291.6509.1605. PMID: 3935204; PMCID: PMC1418455. 14: Patel KR, Tullett WM. Comparison of two calcium antagonists, verapamil and gallopamil (D-600), in exercise-induced asthma. Eur J Respir Dis. 1985 Oct;67(4):269-71. PMID: 4076366. 15: Chan KW, Lee HS, Ti TY, Tan TH, Feng PH. A comparative study of the use of choline theophyllinate and a sustained-release theophylline in adults with chronic asthma. Ann Acad Med Singap. 1985 Jul;14(3):470-4. PMID: 4073814. 16: Berg SJ, Balant LP, Clarke I, Fairfax AJ. Slow release choline theophyllinate (Sabidal SR 270) in chronic asthma. Br J Clin Pharmacol. 1985 Jul;20(1):89-90. doi: 10.1111/j.1365-2125.1985.tb02804.x. PMID: 4027142; PMCID: PMC1400634. 17: Hsu K, Garton A, Sproule BJ, Tam YK, Legatt D, Herbert FA. The influence of orally administered cimetidine and theophylline on the elimination of each drug in patients with chronic airways obstruction. Am Rev Respir Dis. 1984 Nov;130(5):740-3. doi: 10.1164/arrd.1984.130.5.740. PMID: 6497156. 18: Kreisman H, Cohen C, Ghezzo H, Vickerson F, Frank H, Wolkove N. Combined therapy with ipratropium and theophylline in asthma. Ann Allergy. 1984 Feb;52(2):90-3. PMID: 6230034. 19: Koëter GH, Meurs H, Jonkman JH, de Vries K. Protective effect of choline theophyllinate on histamine, acetylcholine, and propranolol-induced airflow obstruction. Respiration. 1984;45(2):139-46. doi: 10.1159/000194610. PMID: 6729259. 20: Vernon DR, Hole DJ, Stack BH. Theophylline compounds in patients with reversible airways obstruction. Clin Allergy. 1984 Jan;14(1):69-73. doi: 10.1111/j.1365-2222.1984.tb02192.x. PMID: 6697474.